pharma · Pulmonary Embolism · Carcinoma, Hepatocellular
Bayer HealthCare Animal
Bayer HealthCare AG
Bayer HealthCare AG is a pharma organization headquartered in EU. Primary therapeutic focus areas include Pulmonary Embolism, Carcinoma, Hepatocellular, Colorectal Neoplasms, Macular Edema, Prevention of Ischemic Stroke.
3915 S 48TH STREET TER, St. Joseph, Missouri 64503, us HQ
1919 Founded
8 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 3915 S 48TH STREET TER, St. Joseph, Missouri 64503, us
- Founded
- 1919
- Employees
- 8
- Programs
- 34
- Drugs
- 32
- Patents
- 24
Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
Phase 2 · small molecule · Carcinoma, Hepatocellular
Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin for Carcinoma, Hepatocellular is a Phase 2 program (small_molecule) at Bayer HealthCare AG with 1 ClinicalTrials.gov record(s).
Internal code 11546
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Bayer HealthCare AG
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Carcinoma, Hepatocellular
- Status
- completed
- Trials
- 1